Dependence on Revenue from PTCA Guidewires
First written in FY2016. 8 of 15 entries say "Worsened", first in FY2018. Latest entry: FY2026.
Asahi Intecc moved to the "Worse" side of this theme in 2018, 5 years before the typical company in this theme (2023).
The whole theme swung hardest in 2024: 13 of 48 companies on the "Worse" side.
3 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Consolidated sales of our group's core PCI guidewire products totaled ¥70.424 billion in the fiscal year, accounting for 48.4% of total consolidated sales.」
PCI guidewire sales totaled ¥70.424 billion, accounting for 48.4% of consolidated sales, up from 48.2% in the previous fiscal year, indicating greater dependence on the product. - FY2026-H1Updated cardiovascular revenue for the interim periodAnnual report
「Cardiovascular 47,450 — 47,450」
Cardiovascular revenue for the interim consolidated accounting period was ¥47.450 billion. The proportion of consolidated revenue attributable solely to PCI guidewires was not provided. - FY2025WorsenedAnnual report
「Consolidated revenue from the Group's main product, PCI guidewires, was ¥57.812 billion in the fiscal year, accounting for 48.2% of total consolidated revenue. Accordingly, trends in PCI guidewire sales may affect the Group's performance.」
The PCI guidewire sales mix increased from 47.4% in the previous fiscal year to 48.2%, with sales of ¥57.812 billion. Dependence on the main product increased. - FY2025-H1Updated interim-period revenue for the cardiovascular fieldAnnual report
「Cardiovascular 42,390 — 42,390」
Cardiovascular revenue for the interim consolidated accounting period was ¥42.390 billion. The interim report does not include a risk explanation stating the proportion of consolidated revenue attributable to PCI guidewires. - FY2024WorsenedAnnual report
「Consolidated revenue from the Group's main product, PCI guidewires, was ¥50.952 billion in the fiscal year, accounting for 47.4% of total consolidated revenue. Accordingly, trends in PCI guidewire sales may affect the Group's performance.」
PCI guidewire sales were ¥50.952 billion, representing 47.4% of consolidated revenue, and dependence increased from 45.3% in the previous fiscal year. - FY2024-Q3Updated cumulative third-quarter revenue for the cardiovascular fieldAnnual report
「The cardiovascular field performed well in all regions, led by PCI guidewires and penetrating catheters.」
Cardiovascular revenue was ¥54.014 billion, up from ¥46.369 billion in the same period of the previous fiscal year. Sales growth for PCI guidewires and other main products was updated, but no new sales-mix information was provided. - FY2024-Q1Updated quarterly sales growth for the main PCI guidewire productAnnual report
「The cardiovascular field performed very well, led by PCI guidewires and penetrating catheters.」
The cardiovascular field performed well in the first quarter, led by PCI guidewires and penetrating catheters, but no new figures indicating dependence, such as the sales mix, were provided. - FY2023SoftenedAnnual report
「Consolidated revenue from the Group's main product, PCI guidewires, was ¥40.823 billion in the fiscal year, accounting for 45.3% of total consolidated revenue.」
Dependence on PCI guidewire sales declined from 46.0% in the previous fiscal year to 45.3%. However, sales were ¥40.823 billion, and dependence on the main product remained high. - FY2022WorsenedAnnual report
「Consolidated revenue from the Group's main product, PCI guidewires, was ¥35.730 billion in the fiscal year, accounting for 46.0% of total consolidated revenue. Accordingly, trends in PCI guidewire sales may affect the Group's performance.」
The main product is now described as PCI guidewires, with sales of ¥35.730 billion and a higher dependence ratio of 46.0% of consolidated revenue. - FY2021WorsenedAnnual report
「Consolidated revenue from the Group's main product, PTCA guidewires, was ¥27.405 billion in the fiscal year, representing 44.6% of consolidated revenue and indicating a high degree of dependence. Accordingly, trends in PTCA guidewire sales may affect the Group's performance.」
The PTCA guidewire sales ratio increased from 43.4% in the previous fiscal year to 44.6%, with sales of ¥27.405 billion. - FY2020WorsenedAnnual report
「Consolidated revenue from the Group's main product, PTCA guidewires, was ¥24.562 billion in the fiscal year, representing 43.4% of consolidated revenue and indicating a high degree of dependence. Accordingly, trends in PTCA guidewire sales may affect the Group's performance.」
PTCA guidewire sales were ¥24.562 billion, representing 43.4% of consolidated revenue, and dependence increased from 41.5% in the previous fiscal year. - FY2019WorsenedAnnual report
「Consolidated revenue from the Group's main product, PTCA guidewires, was ¥23.758 billion in the fiscal year, representing 41.5% of consolidated revenue and indicating a high degree of dependence. Accordingly, trends in PTCA guidewire sales may affect the Group's performance.」
PTCA guidewire sales were ¥23.758 billion, representing 41.5% of consolidated revenue, and dependence increased from 40.3% in the previous fiscal year. - FY2018WorsenedAnnual report
「Consolidated revenue from the Group's main product, PTCA guidewires, was ¥20.194 billion in the fiscal year, representing 40.3% of consolidated revenue and indicating a high degree of dependence. Accordingly, trends in PTCA guidewire sales may affect the Group's performance.」
Dependence on PTCA guidewire sales increased from 37.7% in the previous fiscal year to 40.3%, with sales of ¥20.194 billion. - FY2017RestatedAnnual report
「Consolidated revenue from the Group's main product, PTCA guidewires, was ¥16.111 billion in the fiscal year, representing 37.7% of consolidated revenue and indicating a high degree of dependence. Accordingly, trends in PTCA guidewire sales may affect the Group's performance.」
Dependence on PTCA guidewires has been updated to sales of ¥16.111 billion and 37.7% of consolidated revenue. - FY2016First statedAnnual report
「Consolidated revenue from the Group's main product, PTCA guidewires, was ¥14.931 billion in the fiscal year, representing 37.8% of consolidated revenue and indicating a high degree of dependence. Accordingly, trends in PTCA guidewire sales may affect the Group's performance.」
PTCA guidewire sales are quantified at ¥14.931 billion, representing 37.8% of consolidated revenue.